Inactive Instrument

Analyst Reco. Curis, Inc. Nasdaq

Equities

HC Wainwright Adjusts Price Target on Curis to $26 From $51, Maintains Buy Rating	Feb. 09	MT
Truist Starts Curis With Buy Rating	Nov. 17	MT
HC Wainwright Cuts Price Target on Curis to $6 From $9, Maintains Buy Rating	23-07-07	MT
HC Wainwright Lowers Price Target on Curis to $9 From $16, Maintains Buy Rating	22-11-10	MT
B. Riley Lowers Curis' Price Target to $10 from $22, Says Emavusertib on Partial Hold but Still Promising; Keeps Buy Rating	22-04-05	MT
Raymond James Downgrades Curis to Market Perform From Outperform	22-04-04	MT
CURIS : Raymond James Starts Curis at Outperform with $15 Price Target	21-10-13	MT
CURIS : Cantor Fitzgerald Adjusts Curis' Price Target to $24 From $15, Maintains Overweight Rating	21-05-13	MT
CURIS : B. Riley Raises Curis' PT to $22 from $19, Notes Room for Further Upside at European Hematology Association Meeting; Keeps Buy Rating	21-05-13	MT
CURIS : B. Riley Starts Curis at Buy with $19 Price Target	21-03-25	MT
CURIS : HC Wainwright Adjusts Curis' Price Target to $16 From $9, Keeps at Buy	21-01-15	MT
CURIS : HC Wainwright Adjusts Curis' Price Target to $9 From $5, Reiterates Buy Rating	20-12-08	MT
CURIS : HC Wainwright Starts Curis at Buy With $5 Price Target	20-11-24	MT

No results for this search